The period is notable as the pandemic was at its peak
Dealmaking in healthcare across private equity, venture capital and mergers and acquisitions touched a peak amid the pandemic during the first half of 2021 both in terms of volume and value, shows a VCCircle analysis.
During the period, the dealmaking in value terms peaked at $4.7 billion and more than doubled from the average of the last four six-monthly periods, shows the analysis of the data from VCCEdge and Tracxn.
According to Ramesh Kannan, Partner, Somerset Indus Capital Partners, pharma, active pharmaceutical ingredients (API) and diagnostics (both products and services) are seeking a huge upside. New public offerings from KIMS, Skanray, Vijaya Diagnostics and Krsnaa Diagnostics is something which one should look out for.
The notable deals during the said period are between PharmEasy acquiring stake in Thyrocare Technologies for Rs 4,546 crore. PharmEasy grabbed another spot on the top deals chart by raising funding from Prosus Ventures, TPG Growth and others.
On the M&A side, the deal value during the period under review was $1.9 billion. The period saw the continuation of an epharmacy consolidation trend that had started during H2 2020 with PharmEasy acquiring Medlife and Reliance Retail buying Netmeds. The first six months of 2021 saw Tata Digital acquire 1mg.